Veranex, a tech-enabled service provider dedicated to the medical technology industry, has acquired Medidee, a medtech consultancy company headquartered in Lausanne, Switzerland.
As a European regulatory and quality service consultancy joining Veranex, Medidee expands and strengthens regulatory affairs, clinical development, and quality assurance services and capabilities for medtech companies. This improved ability to navigate the European Union’s Medical Device and In Vitro Diagnostic Device Regulations (EU-MDR/IVDR) challenges supports full-service medtech product development and commercialisation.
Veranex CEO David Dockhorn, said: “Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage. The combined organisation offers offices and expertise across Europe, the U.S., and Asia, augmenting our ability to help medtech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.”
With Medidee’s 11 locations across Europe, India, and Asia-Pacific, and Veranex’s 13 locations across the U.S., Europe, and China, the company has the reach to serve clients with a full spectrum of integrated concept-to-commercialisation services — design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy, and market access services — all under one umbrella.
Medidee co-founders Kim Rochat, Philippe Etter, and Michael Maier said: “Medidee has a proven track record serving regulatory, clinical, and quality needs for companies of all sizes, with consulting expertise and clinical trial support in increasingly diverse therapeutic areas and technology categories across multiple geographies. With these services, coupled with the global infrastructure of Veranex, we expand expertise and resources for the benefit of our clients as well as for all EU innovative manufacturers wishing to access rapidly and efficiently the U.S. market and beyond. We look forward to providing these additional strengths and capabilities.”